Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome

Pediatr Blood Cancer. 2011 Aug;57(2):336-7. doi: 10.1002/pbc.23144. Epub 2011 Apr 14.

Abstract

Autoimmune lymphoproliferative syndrome (ALPS), a disorder of programmed cell death, could be due to a congenital defect in the Fas signaling pathway or other pathways for apoptosis. Most cases present with lymphoproliferation and certain autoimmune features such as thrombocytopenia, neutropenia, and anemia are due to excessive production of antibodies by B lymphocytes. Majority of cases present within the first few years of life. We report a case of ALPS presenting at birth which was refractory to splenectomy and immunosuppressive therapy, but responded to pentostatin followed by hematopoietic stem cell transplantation (HSCT).

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Autoimmune Lymphoproliferative Syndrome / drug therapy*
  • Combined Modality Therapy
  • Diseases in Twins / drug therapy*
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Infant, Newborn
  • Male
  • Pentostatin / therapeutic use*

Substances

  • Antineoplastic Agents
  • Pentostatin